Reference - Detail
| RRC ID | 52638 |
|---|---|
| Author | Senju H, Kumagai A, Nakamura Y, Yamaguchi H, Nakatomi K, Fukami S, Shiraishi K, Harada Y, Nakamura M, Okamura H, Tanaka Y, Mukae H. |
| Title | Effect of IL-18 on the Expansion and Phenotype of Human Natural Killer Cells: Application to Cancer Immunotherapy. |
| Journal | Int J Biol Sci |
| Abstract |
When pathogenic stresses are recognized by innate immune cells, inflammasomes are assembled and caspase-1 is activated, resulting in the conversion of pro-IL-18 into mature IL-18. Because natural killer (NK) cells express IL-18 receptors, IL-18 may play roles in immune functions of NK cells. In the present study, we examined the effect of IL-18 on NK cells derived from lung cancer patients and healthy adult volunteers. When peripheral blood NK cells were stimulated with IL-2, the cells formed clusters beginning on day 5-6 and proliferated thereafter, in which the number of NK cells increased by 10-fold in 10 days. When IL-18 was added, cell clusters were observed as early as on day 4 and NK cells proliferated vigorously. On day 10, the expansion rate was 56-fold on average, showing that IL-18 promoted the expansion of NK cells. It was also notable that IL-18 enhanced the expression of CD80, CD86, HLA-DR and HLA-DQ on NK cells, suggesting that IL-18 conferred NK cells an APC-like phenotype. When cellular cytotoxicity was determined, APC-like NK cells efficiently killed tumor cells and anti-tumor activity was augmented by the addition of tumor antigen-specific mAbs. In addition, IFN-γ was produced by APC-like NK cells in response to tumor cells, and the cytokine production was further enhanced by mAbs. Taken together, IL-18 not only promoted the expansion of NK cells, but also changed the phenotype of NK cells. IL-2/IL-18-induced NK cells might, therefore, serve as a bridge between innate immunity and adaptive immunity and be useful for cancer immunotherapy. |
| Volume | 14(3) |
| Pages | 331-340 |
| Published | 2018-3-9 |
| DOI | 10.7150/ijbs.22809 |
| PII | ijbsv14p0331 |
| PMID | 29559850 |
| PMC | PMC5859478 |
| MeSH | Adult Antigen-Presenting Cells / immunology Humans Immunophenotyping* Immunotherapy* Interleukin-18 / physiology* Interleukin-2 / physiology K562 Cells Killer Cells, Natural / cytology Killer Cells, Natural / immunology* Neoplasms / immunology* Neoplasms / pathology Neoplasms / therapy* |
| IF | 4.858 |
| Times Cited | 13 |
| Altmetric score |
オルトメトリクス指標項目
|
| The most frequently cited source | Patent(IFI CLAIMS) |
| Total number of mentions | 14 |
| Altmetric score changes over past 6months | 3.0 |
| Resource | |
| Human and Animal Cells | PC-9(RCB4455) |